Inhibrx Files for $75 Million IPO

June 4, 2019

Clinical-stage biotech, Inhibrx filed the paperwork for its IPO. The company will raise up to $74,750,000 and intends to trade on NASDAQ under the symbol, “INBX.” Inhibrx is based in La Jolla, CA and has built a pipeline focused on oncology, orphan diseases and infectious diseases.

Its most advanced development programs are in Ph I trials. These include:

  • INHIBRX-109 - a multivalent agonist of death receptor 5 with potential against multiple tumor types,
  • INHIBRX-105 - a PD-L1 and 4-BB inhibitor with potential against PD-L1 expressing tumors.
  • INHIBRX-103 - an mAb that has been licensed to Celgene

The company announced on May 21, 2019 that it had raised $40 million from Viking Global Partners. Since its inception, Inhibrx has raised $205 million, including $135 million in investor equity and debt and $70 million in licensing and grant payments.


CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.